These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38078382)

  • 1. An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV.
    Guo H; Cho B; Hinton PR; He S; Yu Y; Ramesh AK; Sivaccumar JP; Ku Z; Campo K; Holland S; Sachdeva S; Mensch C; Dawod M; Whitaker A; Eisenhauer P; Falcone A; Honce R; Botten JW; Carroll SF; Keyt BA; Womack AW; Strohl WR; Xu K; Zhang N; An Z; Ha S; Shiver JW; Fu TM
    Emerg Microbes Infect; 2023 Dec; 12(2):2275598. PubMed ID: 38078382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
    Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
    Liu MQ; Jiang RD; Guo J; Chen Y; Yang DS; Wang X; Lin HF; Li A; Li B; Hu B; Wang ZJ; Yang XL; Shi ZL
    J Virol; 2022 Apr; 96(8):e0016922. PubMed ID: 35343762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
    Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
    J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes.
    Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
    Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 442th amino acid residue of the spike protein is critical for the adaptation to bat hosts for SARS-related coronaviruses.
    Li JY; Wang Q; Liao CH; Qiu Y; Ge XY
    Virus Res; 2021 Apr; 295():198307. PubMed ID: 33476695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
    Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
    Mou H; Quinlan BD; Peng H; Liu G; Guo Y; Peng S; Zhang L; Davis-Gardner ME; Gardner MR; Crynen G; DeVaux LB; Voo ZX; Bailey CC; Alpert MD; Rader C; Gack MU; Choe H; Farzan M
    PLoS Pathog; 2021 Apr; 17(4):e1009501. PubMed ID: 33836016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.